Navigation Links
arGEN-X Presents Significant Progress at BioPharm America 2011
Date:9/7/2011

nsforming the therapeutic antibody space. The speed and productivity of our first three internal programs have enabled us to begin discovery work on two new therapeutic targets. These developments have been instrumental in attracting companies seeking a reliable, robust platform for generation of therapeutic grade antibody candidates. Given this progress, I am excited about arGEN-X' prospects for the coming year."

Note for the editor

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company with a broadly applicable, proprietary SIMPLE Antibody™ platform. The platform allows arGEN-X to create an unparalleled diversity of in vivo generated antibody leads against a broad range of human disease targets. This superior choice of ultra-high affinity and highly potent leads, having best-in-class human homology, allows for more stringent lead selection criteria, thereby increasing the probability of success later in the drug development path. The Company has validated its platform on four human disease targets to date and has broad patent claims in place covering its technology.

arGEN-X' SIMPLE Antibody™ Platform is based on the active immunisation of Camelids with target antigens to deliver antibody variable regions that are perfectly matched to those of human antibodies. The combination of those variable domains with the constant domains of human antibodies, generates full size, human therapeutic antibodies.

The SIMPLE Antibody™ Platform enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

arGEN-X™ and SIMPLE Antibody™ are deposited trademarks of arGEN-X BV.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

For further information, please contact:


  
'/>"/>

SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
2. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
3. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
4. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
5. Elan Pharmaceuticals Presents 7th Annual Danville Concours dElegance Weekend
6. Codexis Presents Carbon Capture Update at DoE/NETL Conference
7. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
8. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
9. Amerigroup Foundation Presents Grant to Rx Partnership
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Presents at 6th Annual Executive Forum on Pharmacy Benefit Management Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Product Segments: SPECT Systems (Includes SPECT and SPECT/CT systems), and ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2013 through 2020. Also, a ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Parasiticides, Vaccines, Anti-Infectives, Medicinal Feed Additives, and Others. The report ... Animals. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
(Date:9/16/2014)... , Sept. 16, 2014  ROX Medical ... an international multi-center, prospective, randomized, controlled, blinded endpoint ... of arterial hypertension. The CONTROL-HTN trial, NCT01642498, evaluated the ... a fixed connection between a central artery and ... treatment of hypertension. The primary outcomes are reduction ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Global Animal Medication Industry 2Global Animal Medication Industry 3Global Animal Medication Industry 4Global Animal Medication Industry 5Global Animal Medication Industry 6Global Animal Medication Industry 7Global Animal Medication Industry 8Global Animal Medication Industry 9Global Animal Medication Industry 10Global Animal Medication Industry 11
... studies including a pivotal Phase III trial in patients,with ... tablets will be presented at the Annual,Meeting of the ... June 1 - 5, 2007. , On this occasion ... on June 4, 2007. Starting at around 2:00 p.m. ...
... of Eisai's,Commitment to Oncology, WOODCLIFF LAKE, N.J., May ... abstracts covering clinical data about,their oncology pipeline compounds ... of Clinical Oncology (ASCO),annual meeting. ASCO takes place ... reveal a growing and diverse oncology clinical,development program ...
Cached Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4
(Date:9/16/2014)... 2014 The second federal bellwether trial ... Johnson subsidiary Ethicon concluded with the jury in the ... awarding her $3.27 million in damages, according to a ... “jurors found Ethicon liable for selling faulty devices and ... were at risk from side effects that include pain, ...
(Date:9/16/2014)... September 16, 2014 Advanced Fertility Center ... named by Houstonia Magazine as one of the Top ... Houstonia Magazine - a metropolitan magazine serving the Houston ... and recognize them for their outstanding services. This accomplishment ... edition of Houstonia Magazine — a special publication listing ...
(Date:9/16/2014)... Duke’s Chowder House Lake Union is excited ... Gratafy for a fun evening of tech networking. , ... With the growth of companies in these sectors, there’s also a ... in tech and at startups to connect with each other. ... host events for their peers to meet and mingle in fun, ...
(Date:9/16/2014)... radiation therapy as part of breast conservation is ... hormone-receptor positive (HR+) invasive breast cancer. A new ... however, shows that combination may not be necessary ... , The results, which Fox Chase researchers presented ... Annual Meeting on Sunday, September 14, suggest that ...
(Date:9/16/2014)... This year’s theme is centered around entrepreneurism and ... Pennsylvania, September 15, 2014- Holganix, an elite member of ... companies in the country, produces an organic Bionutritional product ... by naturally decreasing disease and insect damage though significant ... it will hold its third annual Bionutritional Summit at ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... ... in Canada ... MINNEAPOLIS, Jan. 31 ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer and ... request,for additional information and clarification from the US Food and Drug,Administration (FDA) regarding ...
... Minnesota, MINNEAPOLIS, Jan. 31 A new ... percent of Minnesotans support the,statewide smoke-free law, with ... evidence of strong support among all leading,demographics, including ... The survey was conducted by Minneapolis research,firm Decision ...
... closer to understanding why some people suffer from ... the new online open access journal BMC Medical ... accurate prediction of the risk of prostate cancer ... score given to prostate cancer based on its ...
... benefit from annual Give Kids A Smile! events, ... Children,s Dental,Health Month and on Feb. 1, more ... to more than 500,000 children from low-income,families, at ... of the,American Dental Association,s (ADA) sixth annual Give ...
... Jan. 30 The Department of,Labor,s Occupational Safety ... Register that nominations are being accepted for,persons to ... Safety,and Health. The committee was established under section ... 1970 to advise the Secretary of Labor,and the ...
... of Patient-Oriented Research, PHILADELPHIA, Jan. 30 ... Hospital of Philadelphia and the,University of Pennsylvania School ... Institute (HHMI) investigator. Following a nationwide,competition in 2007, ... the prestigious research organization., Like all those ...
Cached Medicine News:Health News:ATS Medical Provides Update on First Generation Tissue Valve Approval 2Health News:ATS Medical Provides Update on First Generation Tissue Valve Approval 3Health News:New Survey Finds 76 Percent of Minnesotans Support Smoke-Free Law 2Health News:Study reveals improved prediction of prostrate cancer 2Health News:Open Wide! Nation's Dentists Address Access With Free Care for Kids 2Health News:Open Wide! Nation's Dentists Address Access With Free Care for Kids 3Health News:OSHA Seeking Nominations for National Advisory Committee on Occupational Safety and Health 2Health News:Genetics Researcher at Children's Hospital Selected as Howard Hughes Medical Institute Investigator 2Health News:Genetics Researcher at Children's Hospital Selected as Howard Hughes Medical Institute Investigator 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: